AURORA, ON, Oct. 24 /CNW/ - Helix BioPharma announced today the publication of a scientific paper in the Journal of Experimental Therapeutics and Oncology (volume 5, number 2, pp. 93-99), entitled "Urease-induced alkalinization of extracellular pH and its antitumour activity in human breast and lung cancers." The paper describes the novel approach of eliminating tumour cells through a combination of pH augmentation and ammonia toxicity. A significant number of human tumours are known to possess an acidic microenvironment as a result of tumour metabolism and physiology. There is also evidence in the literature that suggests that an acidic tumour microenvironment encourages tumour invasion and metastasis. Furthermore, this acidic microenvironment has also been previously shown to function as a barrier to a number of well known chemotherapeutics which are weakly basic in solution, causing the reduction of their therapeutic efficacy. In the present publication, DOS47 is shown to be able to neutralize this hostile microenvironment and promote a potent tumouricidal effect through the breakdown of urea, a metabolite naturally produced by the human body. Research highlights described in the paper include the effects of DOS47 on cultured breast and lung cancer cells. Model animal studies demonstrating the effectiveness of DOS47 are also presented. As well, DOS47 is demonstrated to significantly potentiate the efficacy in cultured cancer cells of a number of chemotherapeutics including doxorubicin and vinblastine, which are used to treat breast and lung cancer patients. About Helix BioPharma Corp. Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The Company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its Topical Interferon Alpha-2b and its novel L-DOS47 new drug candidate. Helix is listed on the TSX under the symbol "HBP". The Toronto and Frankfurt Stock Exchanges have not reviewed and do not accept responsibility for the adequacy or accuracy of the content of this News Release. This News Release contains certain forward-looking statements regarding the Company's DOS47, L-DOS47 and other products, including Topical Interferon Alpha-2b, which statements can be identified by the use of forward-looking terminology such as "evidence", "suggests", "be able to", "promote", "believed", "theorized", "thought to", "specializing", "developing", or variations thereon, or that events "can", "should" or "will" occur, or comparable terminology referring to future events or results. Forward looking statements are statements about the future and are inherently uncertain, and Helix's actual results could differ materially from those anticipated in these forward-looking statements as a result of numerous factors, including without limitation, uncertainty whether clinical trials will be commenced or completed as proposed or at all; uncertainty whether the trial results will show efficacy and safety of DOS47 and L-DOS47 as anticipated or at all; the need for additional clinical trials, the occurrence and success of which cannot be assured; product liability and insurance risks; research & development risks, the risk of technical obsolescence; the need for further regulatory approvals, which may not be obtained in a timely matter or at all; intellectual property risks; marketing/manufacturing and partnership/strategic alliance risks; the effect of competition; uncertainty of the size and existence of a market opportunity for Helix's products; uncertainty as to whether DOS47 and L-DOS47 will be successfully commercialized, or at all; Helix's need for additional future capital, which may not be available in a timely manner or at all; as well as a description of other risks and uncertainties affecting Helix and its business, as contained in news releases and filings with the Canadian Securities Regulatory Authorities, any of which could cause actual results to vary materially from current results or Helix's anticipated future results. Forward-looking statements are based on the beliefs, opinions and expectations of Helix's management at the time they are made, and Helix does not assume any obligation to update any forward-looking statement should those beliefs, opinions or expectations, or other circumstances change.